-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Ok+kbFT8ZD9cYTacDL+TMYje4nIOjdxs6GCfa8L1qBjb6+93VsJkvBU70MneK4oJ IAqyf8bF4L2h+JC43BzkSg== 0000895345-98-000413.txt : 19980729 0000895345-98-000413.hdr.sgml : 19980729 ACCESSION NUMBER: 0000895345-98-000413 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 19980716 ITEM INFORMATION: ITEM INFORMATION: FILED AS OF DATE: 19980727 SROS: NYSE FILER: COMPANY DATA: COMPANY CONFORMED NAME: ICN PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000930184 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330628076 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: SEC FILE NUMBER: 001-11397 FILM NUMBER: 98671438 BUSINESS ADDRESS: STREET 1: 3300 HYLAND AVE CITY: COSTA MESA STATE: CA ZIP: 92626 BUSINESS PHONE: 7146683102 MAIL ADDRESS: STREET 1: 3300 HYLAND AVE CITY: COSTA MESA STATE: CA ZIP: 92626 FORMER COMPANY: FORMER CONFORMED NAME: ICN MERGER CORP DATE OF NAME CHANGE: 19940915 8-K 1 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): JULY 24, 1998 ------------- ICN Pharmaceuticals, Inc. ------------------------- (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-11397 33-0628076 -------- --------- ---------- (State or Other Jurisdiction (Commission (IRS Employer of Incorporation) File Number) Identification No.) 3300 Hyland Avenue Costa Mesa, California 92626 ---------------------- ----- (Address of Principal Executive Offices) (Zip Code) Registrant's telephone number, including area code: (714) 545-0100 -------------- N/A ------------------------------------------------------------- (Former name or former address, if changed since last report) Item 5. Other Events On July 24, 1998, the Registrant issued a press release announcing that it intends to issue $200 million of Senior Notes through a private placement. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ICN Pharmaceuticals, Inc. By /s/ David C. Watt ----------------------------- David C. Watt Executive Vice President, General Counsel and Secretary Date: July 24, 1998 EXHIBIT INDEX Exhibit Number Description - -------------- ----------- 99.1 Text of Press Release issued by the Registrant on July 24, 1998. EX-99.1 2 Exhibit 99.1 [Letterhead of ICN Pharmaceuticals, Inc.] NEWS RELEASE FOR IMMEDIATE RELEASE --------------------- CONTACTS: Media: Kathryn Corbett Investors: Mariann Ohanesian Edelman Financial ICN Pharmaceuticals (212) 704-8292 (714) 545-0100 ICN PHARMACEUTICALS ANNOUNCES PROPOSED -------------------------------------- $200 MILLION DEBT OFFERING -------------------------- NEW YORK, N.Y., July 24, 1998 - ICN Pharmaceuticals, Inc. (NYSE: ICN) today announced that it intends to issue $200 million of Senior Notes through a private placement. It is expected that the transaction will close in August of this year. ICN intends to utilize the proceeds of the offering for general corporate purposes including acquisitions to supplement its expansion program. The notes will not be registered under the Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. This announcement is neither an offer to sell nor a solicitation of an offer to buy these securities. ICN manufactures and markets a broad range of prescription and non-prescription pharmaceuticals and biotechnology research products in over 90 countries and employs some 17,000 people worldwide. ICN has operations in Western, Central and Eastern Europe, North and Latin America, and the Pacific Rim. Additional information is available on the corporate website at http://www.icnpharm.com. THE SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. This press release contains forward-looking statements that involve risks and uncertainties, including but not limited to, projections of future sales, operating income, returns on invested assets, regulatory approval processes, and other risks detailed from time to time in the Company's Securities and Exchange Commission filings. -----END PRIVACY-ENHANCED MESSAGE-----